Precision Nanovaccines for Potent Vaccination.

JACS Au

College of Chemistry and Molecular Science, Henan University, Zhengzhou 450046, China.

Published: August 2024

Compared with traditional vaccines, nanoparticulate vaccines are especially suitable for delivering antigens of proteins, peptides, and nucleic acids and facilitating lymph node targeting. Moreover, apart from improving pharmacokinetics and safety, nanoparticulate vaccines assist antigens and molecular adjuvants in crossing biological barriers, targeting immune organs and antigen-presenting cells (APC), controlled release, and cross-presentation. However, the process that stimulates and orchestrates the immune response is complicated, involving spatiotemporal interactions of multiple cell types, including APCs, B cells, T cells, and macrophages. The performance of nanoparticulate vaccines also depends on the microenvironments of the target organs or tissues in different populations. Therefore, it is necessary to develop precise nanoparticulate vaccines that accurately regulate vaccine immune response beyond simply improving pharmacokinetics. This Perspective summarizes and highlights the role of nanoparticulate vaccines with precise size, shape, surface charge, and spatial management of antigen or adjuvant for a precision vaccination in regulating the distribution, targeting, and immune response. It also discusses the importance of the rational design of nanoparticulate vaccines based on the anatomical and immunological microstructure of the target tissues. Moreover, the target delivery and controlled release of nanovaccines should be taken into consideration in designing vaccines for achieving precise immune responses. Additionally, it shows that the nanovaccines remodel the suppressed tumor environment and modulate various immune cell responses which are also essential.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350730PMC
http://dx.doi.org/10.1021/jacsau.4c00568DOI Listing

Publication Analysis

Top Keywords

nanoparticulate vaccines
24
immune response
12
vaccines
8
improving pharmacokinetics
8
targeting immune
8
controlled release
8
nanoparticulate
6
immune
6
precision nanovaccines
4
nanovaccines potent
4

Similar Publications

Advances in dorzolamide hydrochloride delivery: harnessing nanotechnology for enhanced ocular drug delivery in glaucoma management.

Discov Nano

December 2024

The Novel Drug & Vaccine Delivery Systems Facility, Department of Chemistry and Biochemistry, Laurentian University, Sudbury, ON, P3E 2C6, Canada.

Article Synopsis
  • Dorzolamide hydrochloride (DRZ) is a medication used to lower eye pressure in glaucoma patients, but its effectiveness is limited by a short duration of action and the need for frequent use.
  • Recent advancements in drug delivery systems, such as cyclodextrin complexation and nanotechnology, aim to enhance the bioavailability and effectiveness of DRZ.
  • These innovative systems, including nanoparticle carriers and liposome formulations, provide sustained release and better eye penetration, potentially improving patient compliance and treatment outcomes compared to traditional methods.
View Article and Find Full Text PDF

Lipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective.

Pharmaceutics

October 2024

Department of Bioengineering, iBB-Institute for Bioengineering and Biosciences, Instituto Superior Técnico, University of Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.

Oils and lipids help make water-insoluble drugs soluble by dispersing them in an aqueous medium with the help of a surfactant and enabling their absorption across the gut barrier. The emergence of microemulsions (thermodynamically stable), nanoemulsions (kinetically stable), and self-emulsifying drug delivery systems added unique characteristics that make them suitable for prolonged storage and controlled release. In the 1990s, solid-phase lipids were introduced to reduce drug leakage from nanoparticles and prolong drug release.

View Article and Find Full Text PDF

Glioblastoma (GBM) immunotherapy is particularly challenging due to the pro-tumorigenic microenvironment, marked by low levels and inactive immune cells. Toll-like receptor (TLR) agonists have emerged as potent immune adjuvants but failed to show improved outcomes in clinical trials when administered as a monotherapy. We hypothesize that a combined nanoparticulate formulation of TLR agonist and immunogenic cell death-inducing drug (doxorubicin) will synergize to induce improved GBM immunotherapy.

View Article and Find Full Text PDF

A Polysaccharide-Based Oral-Vaccine Delivery System and Adjuvant for the Influenza Virus Vaccine.

Vaccines (Basel)

September 2024

Department of Pharmaceutical Sciences, College of Pharmacy & Allied Health Professions, South Dakota State University, Brookings, SD 57007, USA.

Influenza virus enters the host body through the mucosal surface of the respiratory tract. An efficient immune response at the mucosal site can interfere with virus entry and prevent infection. However, formulating oral vaccines and eliciting an effective mucosal immune response including at respiratory mucosa presents numerous challenges including the potential degradation of antigens by acidic gastric fluids and the risk of antigen dilution and dispersion over a large surface area of the gut, resulting in minimal antigen uptake by the immune cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!